regorafenib
FDA gives Bayer’s colon cancer drug “priority”
- Thu, 06/28/2012 - 2:29pm
The U.S. Food and Drug Administration accepted Bayer’s experimental drug regorafenib for priority review, which could make it marketable in a matter of six months.
The U.S. Food and Drug Administration accepted Bayer’s experimental drug regorafenib for priority review, which could make it marketable in a matter of six months.
From side effects to recalls to pending lawsuits, Consumer Drug Report keeps you up to date with the latest information on pharmaceutical safety.
To submit questions or story ideas, please post on our Consumer Drug Report Facebook page,
tweet at us @ConsumerDrugRep, or
email us at news@consumer-drug-report.com.
Brought to you by Spangenberg Shibley & Liber, LLP © 2012